Mirum Pharmaceuticals is a clinical-stage therapeutics company focused on developing treatments for cholestatic liver diseases, with an immediate focus on rare pediatric conditions. Its lead product candidate, maralixibat, is an oral inhibitor of the apical sodium dependent bile acid transporter (ASBT) and is Phase 3-ready with an established safety profile and efficacy data in Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). Mirum has an exclusive global rights agreement with Shire to develop and market maralixibat; Shire will receive an upfront payment, an equity position in the company and potential future milestone payments and royalties. The company intends to use the Series A proceeds to continue development of maralixibat for rare cholestatic liver diseases. Mirum’s senior leadership includes chairman and CEO Mike Grey, president Chris Peetz and chief scientific officer Vig, Ph.D. The company is based in San Diego, California.

Total raised

$120M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2018